logo

HINDALCO vs SUNPHARMA: Stock Comparison

HINDALCO INDUSTRIES vs SUN PHARMACEUTICAL IND LUpdated 23 Oct 26, 4:08 PM ISTNSE & company filings

SUN PHARMACEUTICAL IND L is the larger company by market capitalisation. HINDALCO INDUSTRIES shows a lower P/E and faster revenue growth, while SUN PHARMACEUTICAL IND L shows a higher ROE, a higher dividend yield and lower leverage. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

HINDALCO leads 4; SUNPHARMA leads 7 of 13

Not a rating
These companies operate in different sectors (Metals & Mining vs Healthcare). Valuation and leverage norms differ across sectors, so cross-sector ratio comparisons can mislead — compare each against its own sector peers too.

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

HINDALCOSUNPHARMA

Valuation lens

What price are you paying?

Market CapContext only
₹1.93 L Cr
₹4.18 L Cr
P/E RatioHINDALCO has the lower reading
11.79x ✓
34.58x
P/B RatioHINDALCO has the lower reading
1.42x ✓
5x
EPSHINDALCO has the higher reading
₹31.21 ✓
₹12.06
Book ValueContext only
₹607.84
₹349.6
Dividend YieldSUNPHARMA has the higher reading
0.58%
0.92% ✓

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
SUNPHARMA is the larger company
₹4.18 L Cr vs ₹1.93 L Cr
P/E Ratio
HINDALCO has a lower P/E
11.79x vs 34.58x
P/B Ratio
HINDALCO has a lower P/B
1.42x vs 5x
EPS
HINDALCO has higher earnings per share
₹31.21 vs ₹12.06
Dividend Yield
SUNPHARMA has a higher dividend yield
0.92% vs 0.58%
Revenue Growth (TTM YoY)
HINDALCO has faster revenue growth
20.4% vs 12.8%
EPS Growth (TTM YoY)
SUNPHARMA has faster EPS growth
25.6% vs -50.9%
ROE
SUNPHARMA has a higher ROE
13.72% vs 9.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricHINDALCOSUNPHARMA
SectorMetals & MiningHealthcare
IndustryAluminiumPharmaceuticals

Price

MetricHINDALCOSUNPHARMA
Live Price₹869.85₹1,748
Day Change-1.78%-0.57%
Volume76.74 L10.65 L
52-Week High₹1,176₹2,046.9
52-Week Low₹770.15₹1,583.7
Distance from 52W High-26.03%-14.6%

Valuation

MetricHINDALCOSUNPHARMA
Market Cap₹1.93 L Cr₹4.18 L Cr
P/E Ratio11.79x34.58x
P/B Ratio1.42x5x
EPS₹31.21₹12.06
Book Value₹607.84₹349.6
Dividend Yield0.58%0.92%

Growth

MetricHINDALCOSUNPHARMA
Revenue Growth (TTM YoY)20.4%12.8%
EPS Growth (TTM YoY)-50.9%25.6%
Qtr Sales Growth0%0%
Qtr Profit Growth0%0%

Profitability & Leverage

MetricHINDALCOSUNPHARMA
ROE9.8%13.72%
ROCE7.27%15.16%
Net Margin4.87%18.56%
Operating Margin7.99%26.44%
Debt to Equity0.71x0.05x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricHINDALCOSUNPHARMA
Promoter Holding34.01%▲ 0.02 pp52.68%▼ 1.8 pp
FII Holding35.6%▲ 1.47 pp14.36%▼ 0.17 pp
DII Holding19.95%▼ 1.52 pp22.27%▲ 0.09 pp
Public Holding9.1%▲ 0.07 pp10.7%▲ 1.89 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: HINDALCO INDUSTRIES and SUN PHARMACEUTICAL IND L.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.